Breast Cancer

In patients receiving everolimus in clinical trials, stomatitis frequently occurred in the initial weeks of treatment, but this did not compromise clinical outcomes, according to Hope S. Rugo, MD, Professor of Medicine and Director of Breast Oncology and Clinical Trials at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
In breast cancer patients with bone metastasis, less frequent infusion of zoledronic acid was as effective as the standard monthly dose, the randomized OPTIMIZE-2 study showed.
For the first-line treatment of HER2-positive metastatic breast cancer, the combination of eribulin mesylate and trastuzumab yields higher response rates, with manageable toxicity.
Management of ductal carcinoma in situ (DCIS) was the focus of 2 studies highlighted at a premeeting Press Cast for the American Society of Clinical Oncology Breast Cancer Symposium held in San Francisco, California.
For the first-line treatment of HER2-positive metastatic breast cancer, the combination of eribulin mesylate and trastuzumab yields higher response rates, with manageable toxicity.
Advances in breast cancer diagnostics and treatment have led to improved survival for patients with breast cancer. However, survivors still face psychosocial and physical challenges.
Of all newly diagnosed breast cancer, 6% to 10% is metastatic, and a proportion of women with early breast cancer eventually develop metastasis. Treatment of metastatic breast cancer has improved considerably, and patients are living longer with metastatic disease.
Breast cancer survivors who suffer from depression can safely take both tamoxifen and a concomitant selective serotonin reuptake inhibitor (SSRI) antidepressant, according to a large population-based observational study presented at the 2013 annual meeting of the Multinational Association of Supportive Care in Cancer.
Further analyses of Study 301, which compared eribulin to capecitabine in the treatment of advanced breast cancer, showed greater improvements in quality of life (QOL) with eribulin, and overall survival (OS) benefits in subsets of patients.
Further analyses of Study 301, which compared eribulin to capecitabine in the treatment of advanced breast cancer, showed greater improvements in quality of life (QOL) with eribulin, and overall survival (OS) benefits in subsets of patients.
Page 4 of 13
Results 31 - 40 of 121